Data Breach Notification
,
Data Security
,
Healthcare
Inotiv Tells SEC ‘It’s Still Evaluating Full Impact and Notifying Breach Victims’

Drug research firm Inotiv in a filing with federal regulators said it is still evaluating the full financial and operational impact of an August cyberattack that’s linked to ransomware gang Qilin. The company is also notifying nearly 10,000 people whose data was allegedly stolen in the incident.
See Also: New Attacks. Skyrocketing Costs. The True Cost of a Security Breach.
Inotiv in a Dec. 3 filing to the U.S. Securities and Exchange Commission said it has restored availability and access to certain IT systems affected by the cyber incident discovered on Aug. 8.
Inotiv had notified the SEC on Aug. 8 about the attack, saying at the time that its preliminary investigation into the incident found that a threat actor accessed and encrypted certain company systems (see: Drug R&D Firm’s IT, Data Encrypted in Alleged Qilin Attack).
In its fourth quarter files for fiscal 2025 that ended Sept. 30, the company on Dec. 3 told the SEC that during the latest quarter Inotiv incurred about $2.48 million in costs associated with the cyber incident, as well as related to separate legal issues. For the fiscal year, those costs totaled nearly $5.93 million.
Inotiv in its SEC filing did not specify the exact costs so far stemming from the cyberattack and the resulting breach.
The company also did not immediately respond to Information Security Media Group’s requests for financial and other details related to the incident.
“The company is in the process of providing notifications regarding the 2025 cybersecurity incident in accordance with applicable legal obligations,” Inotiv told the SEC. “While we have identified the likely scope of the incident, the full operational and financial impacts are still being evaluated. Accordingly, we have not yet determined whether the 2025 cybersecurity incident is reasonably likely to have a material impact on the company.”
Inotiv in a Dec. 2 breach report to Maine’s attorney general said the incident affected 9,542 people.
The company’s sample breach notification letters submitted to Maine and California’s attorneys general said that Inotiv’s forensics investigation determined that threat actors gained unauthorized access to the firm’s IT systems between Aug. 5 and Aug. 8 and that the hackers “may have acquired certain data.”
The sample letters do not detail the information compromised, beyond stating that names and “other identifiers” were affected. But the letters indicate the compromised data belonged to Inotiv’s current and former employees, their family members, as well as “certain data of other individuals who have interacted with Inotiv or companies it has acquired.”
Inotiv is offering affected individuals complimentary credit monitoring and identity theft protection services for 24 months. The company also reported the incident to law enforcement and that the breach notification was not delayed due to a law enforcement investigation.
As of Wednesday, Inotiv was facing a consolidation of at least three class action lawsuits filed so far in an Indiana federal court stemming from the cyber incident.
The litigation alleges that ransomware group Qilin is believed to be behind the attack, stealing 176 gigabytes of the company’s data. “The cyberattack has caused disruptions to business operations. Additionally, it is believed that Qilin published plaintiffs and class members private information on the darkweb,” the amended consolidated complaint alleged.
The lawsuit, which seeks financial damages, alleges Inotiv failed to properly secure and safeguard the private Information that plaintiffs and class members entrusted to the company.
Attorneys representing the plaintiffs in the litigation against Inotiv did not immediately respond to ISMG’s requests for comment.
Indiana-based Inotiv, which reported revenue of $513 million in fiscal 2025 ending on Sept. 30, is a contract research organization that works with clients in new drug discovery and development in a wide range of therapeutics areas, including cardiovascular, neuroscience, oncology, pulmonary, infectious diseases and many more.
